Сost-effectiveness of pentavalent rotavirus vaccination in the Russian Federation

One of the main causes acute gastroenteritis in children under 5 years age is rotavirus infection (RVI). Vaccines against RVI significantly reduce incidence. Aim. To evaluate cost-effectiveness mass vaccination with a 5-valent vaccine Russian Federation. Materials and methods. The assessment was carried out using modeling based on published data effectiveness epidemiological indicators analysis from perspective health care system society as whole 5-year horizon. cost therapy corresponded to compulsory insurance tariffs for St. Petersburg 2022, price 1 dose registered price, including VAT. Costs life expectancy, taking into account quality, were discounted at 3.5 % per year. Results. Given assumptions made, routine will prevent an average 468,637 cases over years. Avoided direct medical costs, i. e. treatment costs amount 53,4 %, lost income due temporary disability – 46,6 total avoided costs. At same time, volume 61,4 decrease morbidity vaccinated population, 38.6 development indirect effect. predicted person 2,975 thousand rubles. From societal perspective, Rota-V-Aid be 364,813 rubles / QALY (quality-adjusted year), healthcare 1726,399 QALY. Thus, both cases, not exceed generally accepted threshold willingness pay, equal three times gross domestic product capita Federation (according 2021 ~2,7 million rubles). selective lower than that vaccination. Conclusions. Mass only incidence Federation, but, can also considered cost-effective intervention.